Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Emergent BioSolutions Inc (NYSE:EBS)

Delayed Data
As of May 23
 +0.23 / +0.78%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Emergent BioSolutions Inc. is a global specialty biopharmaceutical company focused on the development, manufacture and distribution of a portfolio of medical countermeasures (vaccines, therapeutics and other novel products) and related services for civilian and military populations that address intentional and naturally emerging public health threats, specifically Chemical, Biological, Radiological, Nuclear and Explosive, or CBRNE, threats as well as emerging infectious diseases. The company operations include manufacturing, regulatory affairs, quality assurance, quality control, international sales and marketing and domestic government affairs in support of its portfolio of marketed products, as well as product development and manufacturing infrastructure in support of its portfolio of investigational stage product candidates. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Contact Information

Emergent BioSolutions, Inc.
400 Professional Drive
Gaithersburg Maryland 20879
P:(240) 631-3200
Investor Relations:
(301) 795-1877



Mutual fund holders50.09%
Other institutional41.48%
Individual stakeholders27.40%

Top Executives

Daniel J. Abdun-NabiPresident, CEO & Class III Director
Robert G. KramerCFO, Treasurer & EVP-Corporate Services
W. James JacksonChief Scientific Officer & Senior Vice President
Shauna M. TholenChief Information Officer & Senior Vice President
Laura K. KennedySenior VP, Chief Ethics & Compliance Officer